Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2972

Sort by

Sort Order Select

Journal Articles

Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

Saskia B. Wortmann, Johan L. K. Van Hove, Terry G. J. Derks, Nathalie Chevalier, Vijaya Knight, Andreas Koller, Esmee Oussoren, Johannes A. Mayr, Francjan J. van Spronsen, Florian B. Lagler, Sommer Gaughan, Emile Van Schaftingen, Maria Veiga-da-Cunha

Blood (2020) 136 (9): 1033–1043.

https://doi.org/10.1182/blood.2019004465

Published: 2020

Includes: Supplemental data

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Kristin A. Shimano, MD, Rachael F. Grace, MD, Carolyn M. Bennett, MDMSc, Robert J Klaassen, MD FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 2369.

https://doi.org/10.1182/blood-2019-125487

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

On Demand Plerixafor As a Rescue Strategy in Healthy Donors to Achieve Adequate Stem Cells - a Pilot Study from South India

Kishore Kumar, MBBS, MD DM, Kishore Kumar, MBBS, MD DM, Chezhian Subash, FRCPath

Blood (2019) 134 (Supplement_1): 5640.

https://doi.org/10.1182/blood-2019-127045

Published: 2019

Journal Articles

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Swetha Kambhampati, MD, Derek Galligan, MD, Guy Ledergor, MD, Thomas G. Martin, III, MD, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah, MD

Blood (2019) 134 (Supplement_1): 5576.

https://doi.org/10.1182/blood-2019-122383

Published: 2019

Journal Articles

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Jian Wang, Zimin Sun

Blood (2019) 134 (Supplement_1): 5677.

https://doi.org/10.1182/blood-2019-130138

Published: 2019

Journal Articles

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Nicole Kucine, MD, Shayla Bergmann, MD, Spencer Krichevsky, BS, Devin Jones, MS, Michael E. Rytting, MD, Linda Resar, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4194.

https://doi.org/10.1182/blood-2019-124023

Published: 2019

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia

Blood (2019) 134 (Supplement_1): 2960.

https://doi.org/10.1182/blood-2019-130477

Published: 2019

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

On Demand Plerixafor As a Rescue Strategy in Healthy Donors to Achieve Adequate Stem Cells - a Pilot Study from South India

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only